Health

Team reports on ratiometrically designed nanoprodrug for triple-negative breast cancer treatment

Mammograms show normal breast (left) and breast cancer (right). Credit: Public Domain

Improved therapies are urgently needed to treat triangular breast cancer (TNBC), which is inconsistent with existing treatment regimens. However, the joint strength of a combination of traditional microenvironments is limited primarily due to molar imbalance, drug instability, and single-cell viability. Current nanotechnology offers unparalleled advances in the development of advanced drugs, particularly drug delivery in vivo.

Recently, Prof. Liu Xiangrui and Prof. Zhou Tianhua from Zhejiang University School of Medicine published an article entitled “Nanoprodrug ratiometrically integrating autophagy inhibitor and genotoxic agent for the treatment of triple breast cancer“in Creatures. This study reported glutathione-responsive Combo NP regulated co-administration of hydroxychloroquine (HCQ) and 7-ethyl-10-hydroxycamptothecin (SN38) for the synergistic treatment of metastatic TNBC.

In April 2020, the FDA approved an SN38 source of anticancer drug (sacituzumab govitecan) for the treatment of TNBC patients. SN38 is an inhibitor of topoisomerase I (TOP1), which causes one or two DNA fractures during DNA replication. Evidence suggests that autophagy (“self-sufficiency”) plays an important role in maintaining the stability of cells and regulating DNA repair. The study found that the inhibitor of autophagy HCQ enhances the autophagy of the autophagy cell line. the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle. the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle of the skeletal muscle. HCQ-induced cell proliferation in response to SN38 by induced DNA damage, and found a form of HCQ / SN38 molar synergistic in TNBC cells.

To further enhance the binding effect, they developed nanoprodrug techniques to implement the SN38 and HCQ synthesis. SN38 or HCQ is bound to an amphiphilic polymer by a disulfide bond, which would be particularly cleavable under high GSH levels in tumor cells to release parental drugs, thus avoiding abnormal release in normal tissues. The two polymeric compounds were combined in a uniform consistency in the combo NP nanoparticles at optimal synergistic molar values. Combo NP not only enhances pharmacokinetics and addition of both drugs, but also achieves improved delivery, resulting in improved antitumor function with a free pharmacokinetics in TNBC metastatic mice.

This study focuses on the rationale and methods of genotoxic agent (SN38) research and autophagy inhibitor (HCQ), in parallel, and provides a polymeric-based integration system for overcoming traditional microbial pathogenesis errors, thus providing improved antimicrobial resistance for TBNC treatment.


Analog of Capsaicin may help in the treatment of lung cancer


Learn more:
Huifang Wang et al, Nanoprodrug standard combination anti-autophagy and genotoxic agent for triple breast cancer treatment, Creatures (2022). DOI: 10.1016 / j.biomaterials.2022.121458

Provided by Zhejiang University

hint: The team reports on a costly nanoprodrug manufactured for the treatment of breast cancer three times (2022, April 12) retrieved 12 April 2022 from https://medicalxpress.com/news/2022-04-team -ratiometrically-nanoprodrug-triple-negative-breast .html

This document is copyrighted. Apart from any genuine transaction for research or investigation purposes, any part may not be reproduced without our written permission. Content is provided for informational purposes only.



Team reports on ratiometrically designed nanoprodrug for triple-negative breast cancer treatment Source link Team reports on ratiometrically designed nanoprodrug for triple-negative breast cancer treatment

Related Articles

Back to top button